Deepak Cyril Dsouza, MBBS, MD

Professor of Psychiatry; Director Schizophrenia Neuropharmacology Research Group at Yale (SNRGY); Director, Neurobiological Studies Unit, VACHS; Director, VA-CMHC Schizophrenia Research Clinic

Research Interests

Behavior and Behavior Mechanisms; Mental Disorders; Behavioral Disciplines and Activities; Psychological Phenomena and Processes; Psychiatry and Psychology

Research Organizations

Psychiatry: Clinical Neuroscience Research Unit | Neuroscience Research Training Program (NRTP) | Schizophrenia Research Clinic

Office of Cooperative Research

Research Summary

Our group has been studying the treatment and pathophysiology of schizophrenia. Our work involves the use of various psychopharmacological probes (ketamine, delta-9-THC, iomazenil, etc) to evaluate the contributions of various neurotransmitter systems (NMDA, cannabinoid, GABA, etc) to the pathophysiology of schizophrenia; laboratory studies of comorbid substance abuse in schizophrenia, (alcohol, cannabis and nicotine) and clinical trials with novel agents for schizophrenia.

Extensive Research Description

    • Neurobiology of Cannabis
    • Cannabinoids, Neural Synchrony and Information Processing
    • Cannabinoid Receptor Function in Alcoholism: Effects of D-9-THC
    • Imaging Nicotinic Acetylcholine Receptors in Schizophrenia
    • GABA Deficits and Vulnerability to Cannabinoid-Induced Psychosis
    • GABA Deficits and Vulnerability to Amphetamine-Induced Psychosis
    • Ketamine Nicotine Interactions in Humans
    • Ketamine Interactions with GLYT1 inhibitor in Humans
    • Cognitive Remediation in the Schizophrenia Trials Network
    • Varenicline for Smoking Cessation in Schizophrenia
  • Selected Publications

    Full List of PubMed Publications

    Edit this profile

    Contact Info

    Deepak Cyril Dsouza, MBBS, MD
    Mailing Address
    Psychiatry950 Campbell Avenue
    West Haven, CT 06516